Maduck Sean sold $118K of CORT

Maduck Sean (See Remarks) sold 1,031 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.52 ($0.12M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published Aug 12, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

Traders may monitor insider activity for sentiment, but 10b5-1 plans generally reduce interpretability as a forward-looking signal.

02

Market read

A routine 10b5-1 insider sale is disclosed; it is unlikely to change valuation without accompanying fundamental news.

03

What to watch

The filing does not disclose reasons for the sale, and the relatively small dollar amount ($118K) reduces the likelihood of a material information signal.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-12, sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported by officer Maduck Sean.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

Corcept Therapeutics Form 4 shows officer Maduck Sean sold 1,031 shares on 2026-08-10 at $114.5182, totaling about $118.1K, under a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect would be second-order sentiment rather than a fundamental catalyst.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly under a pre-arranged Rule 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No clear sector read-through; this is company-specific insider trading with no disclosed corporate event.

None.

None.

Counterpoint

Because the sale is on a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, so the market may overreact if it treats it as discretionary selling.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider sale disclosure.

  • Maduck Sean

    Officer who sold 1,031 shares under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.